The University of Chicago Header Logo

Connection

Mark J. Ratain to Animals

This is a "connection" page, showing publications Mark J. Ratain has written about Animals.
Connection Strength

0.238
  1. Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther. 2009 Feb; 85(2):134-5.
    View in: PubMed
    Score: 0.022
  2. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007 Oct; 82(4):381-8.
    View in: PubMed
    Score: 0.020
  3. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004 Jun; 75(6):495-500.
    View in: PubMed
    Score: 0.016
  4. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):52-5.
    View in: PubMed
    Score: 0.015
  5. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
    View in: PubMed
    Score: 0.014
  6. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May; 19(2):171-7.
    View in: PubMed
    Score: 0.013
  7. Gazing into a crystal ball-cancer therapy in the post-genomic era. Nat Med. 2001 Mar; 7(3):283-5.
    View in: PubMed
    Score: 0.013
  8. 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest. 1999; 17(7):494-506.
    View in: PubMed
    Score: 0.011
  9. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998 Feb 15; 101(4):847-54.
    View in: PubMed
    Score: 0.010
  10. Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol. 1998; 42 Suppl:S31-43.
    View in: PubMed
    Score: 0.010
  11. Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res. 1997 Jul; 3(7):1025-30.
    View in: PubMed
    Score: 0.010
  12. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol. 1997; 39(5):440-4.
    View in: PubMed
    Score: 0.009
  13. Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov; 8(6):525-34.
    View in: PubMed
    Score: 0.009
  14. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
    View in: PubMed
    Score: 0.009
  15. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res. 1996 Mar 15; 56(6):1309-14.
    View in: PubMed
    Score: 0.009
  16. Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther. 2013 Oct; 347(1):181-92.
    View in: PubMed
    Score: 0.007
  17. Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol. 1992 Aug; 19(4 Suppl 11):8-13.
    View in: PubMed
    Score: 0.007
  18. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
    View in: PubMed
    Score: 0.006
  19. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.006
  20. Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
    View in: PubMed
    Score: 0.005
  21. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics. 2008 Apr 22; 33(2):278-91.
    View in: PubMed
    Score: 0.005
  22. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007 Mar; 81(3):328-45.
    View in: PubMed
    Score: 0.005
  23. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol. 2002 Apr; 49(4):336-41.
    View in: PubMed
    Score: 0.003
  24. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999 Aug 04; 91(15):1281-7.
    View in: PubMed
    Score: 0.003
  25. Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin Oncol. 1992 Jun; 19(3 Suppl 9):84-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.